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Yi Liu, Gang Chen*, Yi Wu, Renwang Liu, Song Xu, Jun Chen* and Qinghua Zhou*Abstract
Background: A malignant fibrous histiocytoma (MFH) rarely originates from the chest wall.
Clinical findings: In this case, we describe a 59-year-old Chinese woman who presented with an enormous mass
originating from the left chest wall and involving the left upper pulmonary lobe.
Therapy: After a radical en-block resection of the entire chest mass with left upper pulmonary lobectomy, and the
chest wall reconstruction, a histopathologic diagnosis of the giant cell MFH was rendered. She has done well
postoperatively, showing no local recurrence or distal disease in an 8-month follow-up period.
Conclusion: Although a MFH originating from the chest wall is rare, it should be considered in the differential
diagnosis of a chest wall tumor.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8895569301129379
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Malignant fibrous histiocytoma (MFH) is a common soft
tissue sarcoma, which is often found in adults with pri-
mary location of the extremities or retroperitoneum.
However, MFH rarely originates from the chest wall [1].
Here we report the case in a 59-year old woman with a
left chest big mass involving the left upper pulmonary
lobe that was initially suspicious of lung carcinoma in-
vading the chest wall. Ultimately, the chest wall giant
cell malignant fibrous histiocytoma was confirmed fol-
lowing en-block resection of chest wall mass and left
upper lobectomy.
Case presentation
A 59-year-old Chinese woman was admitted to the hos-
pital with the chief complaint of a progressively enlar-
ging mass in the left thoracic wall over the past seven
months. At the initial examination, the tumor slightly* Correspondence: chengang450@163.com; huntercj2004@yahoo.com;
zhouqh135@163.com
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stated.protruded from the chest wall with the 2 cm in diameter,
and gradually grew over in the past several months. In
one month ago, she underwent a percutaneous transtho-
racic needle biopsy of the mass in another hospital. Fol-
lowing the puncture, the tumor promptly increased
significantly in size, impacting blood flow to the left
arm. On this admission, we conducted a physical exam-
ination and palpated the soft painless left lateral chest
wall large mass with the 9 cm in diameter. She denied
smoking history and had no family history of lung can-
cer. A review of her systems was noncontributory. The
results of a peripheral blood count, baseline serum
chemistry screening, and urinalysis were normal on ad-
mission, as were tumor biomarker tests and a purified
protein derivative test for tuberculosis.
Enhanced chest computed tomography (CT) with three-
dimensional reconstruction of the ribs showed an enor-
mous soft tissue mass in the left chest wall (Figure 1),
which extended into the left lung and mediastinum,
exerted pressure on the heart, skewing it to the right, and
had eroded the middle portion of the fifth rib. The density
of the tissue mass was uneven and a necrotic area wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Enhanced chest CT scan before operation. A: In the mediastinal window, the CT scan revealed the tumor encroaching on the
superior vena cava (right panel), surrounding the right upper lobe bronchus (middle panel), and invading the right pulmonary artery (left panel).
B: In the lung window. C: In the mediastinal window, coronal.
Figure 2 Histopathological images. (A) Gross features of the 20 cm
mass with the invaded fifth rib and the left upper pulmonary lobe;
(B) Hematoxylin and eosin (H&E) staining of a giant cell malignant
fibrous histiocytoma cell tumor. (C) Immunohistochemical staining of
primary tumor with antibodies to CD68 (+), Vimentin (+), CK (−),
S-100 (−) and SMA (−).
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tumor mass was 13.3 × 15.7 cm2. Moreover, an ECT bone
scan also demonstrated the destruction of the middle of
the fifth rib. In additional, a CT scan of her abdomen and
magnetic resonance imaging of her brain were all normal.
Her bronchial tree also appeared normal on broncho-
scopic examination, with no indication of malignancy in
the biopsy and washings procured.
After anesthesia and a double-lumen intubation had
been established, a left posterolateral incision was per-
formed. The chest wall tumor invaded the left upper
pulmonary lobe as well as the fourth, fifth, and sixth
ribs. The tumor had eroded the middle portion of the
fifth rib; the heart was impacted by the tumor and medi-
astinal pleural adhesions were present. We freed-up the
outer margin of the tumor and excised the fourth, fifth,
and sixth ribs. Intercostal tissue was included with a
margin over 5 cm. We extracted the tumor and the in-
vaded left upper lobe of lung to remove the pressure on
the heart. We then performed the left upper pulmonary
lobectomy. Finally, we joined four 10 × 10 cm2 polyester
surgical patches (knitted type) into one 20 × 20 cm2
patch and this patch was sutured to the chest wall defect
for chest wall reconstruction.
The neoplasm, which was removed by surgical resec-
tion, weighed 2.080 kg and was 20 cm× 18 cm× 9 cm
in size, as shown in Figure 2A. There were multiple
nodules on its surface and a cross section of the tumor
was honeycombed in appearance. The pathology report
described a giant cell malignant fibrous histiocytoma
cell tumor (Figure 2B), with the immunohistochemistry
of CD68 (+), Vimentin (+), SMA, CK and S-100 (−)
(Figure 2C), invading the left upper lung lobe and the
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ses to the mediastinal lymph nodes. Her postoperative
course was uneventful. She was discharged 12 days after
surgery and showed no signs of local recurrence or dis-
tal disease at an 8-month follow-up visit (Figure 3).
Discussion
A MFH is the most common soft tissue tumor found in
adults. It is primarily located in the extremities or retro-
peritoneum; however, it rarely appears on the chest wall.
A MFH was first reported by O’Brien and Stout in 1964
[2]. They described it as “malignant fibrous xanthoma”.
The tumor preferentially involves the deep fascia, skel-
etal muscles, or superficial subcutaneous tissue. A MFH
has a high propensity for local recurrence and distant
metastases. Weiss and Enzinger [3] reported that a local
recurrence rate of 44% and metastatic recurrence rate of
42% for MFHs. Several MFH subtypes have been de-
scribed in the literature: storiform-pleomorphic, giant
cell, inflammatory, and myxoid [4]. The mean survival of
patients without surgery is 11.7 months; it is 23.2 months
for patients who undergo surgery [5]. MFHs have been
reported to occur with increasing frequency in patients
treated with radiotherapy for other malignant diseases;
however, no prior exposure to ionizing radiation or his-
tory of malignancy was documented in our case. The role
of either chemotherapy or radiotherapy as primary or ad-
juvant treatment for MFHs is currently unclear. Favorable
factors for MFHs are: UICC/AJCC stage I and II, superfi-
cial location, myxoid type, and patient under 50 years of
age. Under these conditions, the rational for radical en-
block resection of the tumor is supported [6-10].
CT and magnetic resonance imaging are useful for the
radiological evaluation of the soft tissue component. Ac-
cording to one report, the imaging features of MFHs inFigure 3 CT scans after operation. The chest CT scan was performed in
lung window.the chest wall are nonspecific and only the myxoid type
showed a high-intensity pattern with T1 weighed images
(T1WI) and T2 weighted images (T2WI). The mass usu-
ally shows intense enhancement on CT with a clear mar-
gin separating it from the surrounding tissue [11].
For a chest wall MFH, wide resection is the first treat-
ment choice; chemotherapy should also be considered.
King reported the relationship between the distance of
the lateral margin of the excision from the tumor and
the recurrence rate. They found a distance of 4 cm was
associated with a recurrence rate of 44%; whereas a dis-
tance of 2 cm was associated with a 71% recurrence rate
[12]. They recommended an excisional distance of 4 cm.
Naoya Yoshida et al. reviewed 39 MFH cases and found
that patients with a negative surgical margin were alive
without recurrence, irrespective of the surgical margin
distance [12].
After radical en-block resection, the chest wall should
be reconstructed. Classically, various flaps such as a
major pectoral muscle flap, a major pectoral myocuta-
neous flap, or a latissimus dorsi myocutaneous flap and
pedicled omentum have been utilized for reconstruction.
Currently, reconstruction with Marlex mesh is widely
used. Several studies have reported that a chest wall re-
construction with Marlex mesh is successful and inexpen-
sive. In this case, the chest wall defect was too large for
reconstruction with a flap. We performed the reconstruc-
tion with a polyester surgical patch (knitted type), and we
joined four 10 × 10 cm2 patches into one 20 × 20 cm2
patch to reconstruct the chest wall. Postoperative compli-
cations such as skin dehiscence, skin necrosis, and infec-
tion did not occur. We found that reconstruction of the
chest wall with a polyester surgical patch for a large defect
is safe, rapid, and simple. We consider that radical en-
block resection for an enormous chest wall MFH and7 days after the operation. A: In the mediastinal window; B: In the
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term survival.
In differential diagnosis of a chest wall tumor, malignant
fibrous histiocytoma should be seriousely considered.
Conclusion
Malignant fibrous histiocytoma be considered in the dif-
ferential diagnosis of a chest wall tumor.
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